Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population

versus docetaxel
atezolizumab alone
OAK (all population), 2016
  NCT02008227
RCTmNSCLC - L2 - all populationatelozumabdocetaxelpatients with locally advanced or metastatic (IIIB and IV) non-small cell lung cancer (NSCLC) who have failed platinum therapy613 / 612some concern
conclusif
  • demonstrated 20 % decrease in deaths (OS) (PE)
POPLAR, 2016
  NCT01903993
RCTmNSCLC - L2 - all populationatezolizumabdocetaxelpatients with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy144 / 143some concern
conclusif
  • demonstrated 27 % decrease in deaths (OS) (PE)